Condition: Non-Functioning Pituitary Adenoma

Study to assess the Efficacy of the Chimeric Dopamine-Somatostatin receptor agonist, TBR-760, in adult patients with Non-Functioning Pituitary Adenoma over 52 weeks.

This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy, PK, and PD of the chimeric dopamine-somatostatin receptor agonist, TBR-760, in adult patients with non-functioning pituitary adenomas over 52 weeks

Location(s): Jacksonville (Headquarters)

Condition: Non-Functioning Pituitary Adenoma